Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

H&O  What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB  Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]

Emerging Therapeutic Targets in Follicular Lymphoma 

  H&O  What is the objective of the Wendel Laboratory? HGW  We are interested in understanding the genetic and biologic mechanisms that lead to cancer in […]